Matteo Lambertini

Jan 13, 2025 | cancernetwork.com | Paolo Tarantino |Matteo Lambertini

January 13, 2025By Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024. Following the 2024 San Antonio Breast Cancer Symposium (SABCS), Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD, co-hosted a live X Space with CancerNetwork® and spoke about updated trial findings that may impact the breast cancer treatment paradigm.

Aug 28, 2023 | esmo.org | Matteo Lambertini

The Young Oncologist (YO) Track Sessions are specially designed by young oncologists for young oncologists and initiated by the ESMO Young Oncologist Committee (YOC). The sessions are educational and cover topics which are highly relevant to YOs in their daily practice, career development and/or research activities.

Jul 25, 2023 | healio.com | Jennifer Southall |Mindy Valcarcel |Matteo Lambertini

Source/Disclosures Disclosures: Ginsburg, Jorgensen and Lambertini report no relevant financial disclosures. Source/Disclosures Disclosures: Ginsburg, Jorgensen and Lambertini report no relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Jul 25, 2023 | fal.cn | Jennifer Southall |Mindy Valcarcel |Kirsten Jorgensen |Matteo Lambertini

Source/Disclosures Disclosures: Ginsburg, Jorgensen and Lambertini report no relevant financial disclosures. Source/Disclosures Disclosures: Ginsburg, Jorgensen and Lambertini report no relevant financial disclosures. You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later.

Jul 19, 2023 | onclive.com | Matteo Lambertini |Virginia Kaklamani

Transcript:Virginia G. Kaklamani, MD, DSc: One of the questions that always comes in, usually from patients, is [about] the timing. You have a woman; you see her preoperatively. She just [received a diagnosis of] ER-positive breast cancer. She’s going to have surgery or triple negative [breast cancer treatment], and she’s going to have neoadjuvant chemotherapy, but there it’s a little more clear.